Cholesterol & Lipid
Sort by:
Houston Methodist DeBakey Heart and Vascular Center
Debate: CCTA and FFR-CT Should Be the First Choice in the Assessment of Suspected CAD: Pro
FEATURING
Jonathon Leipsic
- 615 views
- January 5, 2022
- 10
National Lipid Association
Primary Prevention: A Primer on Cholesterol Screening and Treatment of Hypercholesterolemia in Youth
FEATURING
Don P. Wilson
- 789 views
- October 11, 2023
- 10
National Lipid Association
Is Our Destiny Written for FH and Lp(a)?
FEATURING
Joshua Knowles
- 2,027 views
- October 11, 2023
- 10
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
Role of Inflammation in Cardiovascular Disease
FEATURING
Maria Rosa Costanzo
- 665 views
- March 6, 2024
- 10
Cardiometabolic Health Congress (CMHC)
CMHC Highlights: Discussion on Lipids and Atherosclerosis Risk Assessments
- 812 views
- January 18, 2022
- 9
ASPC 2019 Congress on CVD Prevention
Newer Insights Into Why the SGLT2s Reduce Heart Failure in Patients With Diabetes
FEATURING
Robert Chilton
- 1,410 views
- August 9, 2019
- 10
The Texas Heart Institute
Updates in Guidelines for the Management of Chronic Coronary Artery Disease: What We Should Pay Closer Attention To
FEATURING
Salim Virani
- 848 views
- March 15, 2024
- 10
Houston Methodist DeBakey Heart and Vascular Center
Update on Inflammation & Atherosclerosis Treatment: Should All Atherosclerosis Patients Receive Aggressive Lipid-Lowering and Inflammation Inhibiting Therapy? Why Not Combine Anti-Inflammatory Therapy with PCSK9 Inhibition?
FEATURING
Paul Ridker
- 1,523 views
- July 14, 2020
- 9
Top Ten Topics in Clinical Cardiology 2022
What’ll be New in Lipid Management in 2023? Rethinking the Paradigms
FEATURING
Robert Rosenson
- 3,180 views
- November 21, 2022
- 10
Cleveland Clinic | 12th Annual Obesity Summit
Management of Hypertension and Hyperlipidemia in Type 2 Diabetes
FEATURING
Steven Nissen
- 2,151 views
- December 3, 2017
- 8
Penn Medicine Heart and Vascular Center
Lipoprotein(a) and Cardiovascular Risks: New Insights
FEATURING
Vera Bittner
- 1,960 views
- December 19, 2023
- 10
The Texas Heart Institute
Non-Statin Therapies, Expert ACC Consensus
FEATURING
Christie Ballantyne
- 1,261 views
- September 7, 2023
- 10
"Princeton 4: PDE5 Inhibitors and Cardiac Health Symposium.” Huntington Medical Research Institutes, Pasadena, CA. Friday, March 10th, 2023.
Is ED an Independent Risk Factor or Risk Marker for Cardiovascular Disease and What Is the Role of CT Calcium Scoring?
FEATURING
Michael Blaha
- 1,145 views
- July 13, 2023
- 10
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
Novelties in Lipid Lowering Therapies: Can Statin Therapy Reduce Residual Risk? How Promising Are Icosapent Ethyl, Bampedoic Acid, Inclisiran and Evinacumab for Treating the Patients?
FEATURING
Pam Taub
- 919 views
- February 5, 2021
- 10
ASPC 2018 Congress on CVD Prevention
Debate – Pro – Lipoprotein(a) – Should Be Measured In All Patients At Higher CVD Risk
FEATURING
Patrick Moriarty
- 833 views
- August 10, 2018
- 10
ASPC 2019 Congress on CVD Prevention
LDL-C lowering and the Brain: Differentiating Fact from Fiction
FEATURING
Peter Toth
- 682 views
- August 9, 2019
- 8
The Texas Heart Institute
The 2022 ACC Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour
FEATURING
Christie Ballantyne
- 2,124 views
- February 8, 2023
- 9
Advances in Cardiovascular Disease Prevention
Lifestyle Management to Reduce Cardiovascular Risk
FEATURING
Andrew Freeman
- 1,562 views
- October 22, 2018
- 9
Top Ten Topics in Clinical Cardiology 2021
Cardiovascular Inflammation: Think Local, Act Global
FEATURING
Peter Libby
- 1,006 views
- November 2, 2021
- 9
National Lipid Association
Update on Evinacumab: ANGPTL3 and Lipid Management
FEATURING
P. Barton Duell
- 792 views
- March 20, 2020
- 9